Company registration number 10076390 (England and Wales)
ESI PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
PAGES FOR FILING WITH REGISTRAR
ESI PHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
ESI PHARMA LTD
BALANCE SHEET
AS AT
31 MARCH 2024
31 March 2024
- 1 -
2024
2023
Notes
£
£
£
£
Current assets
Cash at bank and in hand
117
47
Creditors: amounts falling due within one year
4
(1,970)
(1,181)
Net current liabilities
(1,853)
(1,134)
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
(1,854)
(1,135)
Total equity
(1,853)
(1,134)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 25 March 2025
Mr E Bewketu
Director
Company registration number 10076390 (England and Wales)
ESI PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
- 2 -
1
Accounting policies
Company information

Esi Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 35 Hamble Street, London, Fulham, SW6 2RT.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention.

1.2
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.3
Financial instruments

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the financial instrument.

Basic financial assets

Debtors do not carry interest and are stated at their nominal value. Appropriate allowances for estimated irrecoverable amounts are recognised in the Profit and Loss account when there is objective evidence that the asset is impaired.

Basic financial liabilities

Creditors are not interest bearing and are included at their nominal value.

1.4
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.5
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

ESI PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
- 3 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
1
4
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
1,147
709
Other creditors
423
72
Accruals and deferred income
400
400
1,970
1,181
2024-03-312023-04-01falsefalsetrue25 March 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMr E Bewketu100763902023-04-012024-03-31100763902024-03-31100763902023-03-3110076390core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3110076390core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3110076390core:CurrentFinancialInstruments2024-03-3110076390core:CurrentFinancialInstruments2023-03-3110076390core:ShareCapital2024-03-3110076390core:ShareCapital2023-03-3110076390core:RetainedEarningsAccumulatedLosses2024-03-3110076390core:RetainedEarningsAccumulatedLosses2023-03-3110076390bus:Director12023-04-012024-03-31100763902022-04-012023-03-3110076390bus:EntityHasNeverTraded2023-04-012024-03-3110076390bus:PrivateLimitedCompanyLtd2023-04-012024-03-3110076390bus:SmallCompaniesRegimeForAccounts2023-04-012024-03-3110076390bus:FRS1022023-04-012024-03-3110076390bus:AuditExemptWithAccountantsReport2023-04-012024-03-3110076390bus:FullAccounts2023-04-012024-03-31xbrli:purexbrli:sharesiso4217:GBP